Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10072-021-05409-6 http://scihub22266oqcxt.onion/10.1007/s10072-021-05409-6 34165650!8223191!34165650     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34165650&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Neurol+Sci 2021 ; 42 (9): 3533-3535 Nephropedia Template TP {{tp|p=34165650|t=2021. MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine |pdf=|usr=}}{{34165650}} gab.com Text MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine JO: Neurol Sci http://www.kidney.de/pget.php?&tw=1&pmid=34165650 #FOAvip BACKGROUND: The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs' immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as the post-infection development of immunity against the virus under these treatments due to their interaction with the immune system. METHODS: We report two asymptomatic cases of COVID-19 in patients with relapsing-remitting multiple sclerosis (RRMS) shortly after starting cladribine therapy, both developed anti-SARS-CoV-2 antibody response. RESULTS: Patients with MS who are under newly initiated treatment with cladribine tablets may experience an asymptomatic COVID-19 infection and they may develop immunity against SARS-CoV-2. CONCLUSION: These observations raise the probability that DMTs with immunosuppressive effects, such as cladribine, may be considered as a treatment option for selected MS patients with high disease activity during the COVID-19 pandemic. Twit Text FOAVip MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine ????Neurol Sci http://www.kidney.de/pget.php?&tw=1&pmid=34165650 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34165650 #FOAvip English Wikipedia <ref>{{Cite pmid|34165650}}</ref> MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine #MMPMID34165650 Seferoglu M; Ethemoglu O; Turan OF; Siva A Neurol Sci 2021[Sep]; 42 (9): 3533-3535 PMID34165650show ga BACKGROUND: The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs' immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as the post-infection development of immunity against the virus under these treatments due to their interaction with the immune system. METHODS: We report two asymptomatic cases of COVID-19 in patients with relapsing-remitting multiple sclerosis (RRMS) shortly after starting cladribine therapy, both developed anti-SARS-CoV-2 antibody response. RESULTS: Patients with MS who are under newly initiated treatment with cladribine tablets may experience an asymptomatic COVID-19 infection and they may develop immunity against SARS-CoV-2. CONCLUSION: These observations raise the probability that DMTs with immunosuppressive effects, such as cladribine, may be considered as a treatment option for selected MS patients with high disease activity during the COVID-19 pandemic. |*COVID-19[MESH] |*Multiple Sclerosis, Relapsing-Remitting/drug therapy[MESH] |*Multiple Sclerosis/drug therapy/epidemiology[MESH] |Cladribine/therapeutic use[MESH] |Humans[MESH] |Immunosuppressive Agents/therapeutic use[MESH] |Pandemics[MESH]MS and COVID-19 challenge: asymptomatic COVID-19 infection during trea(epmc).pdf DeepDyve Pubget Overpricing